Cytogenetic and loss of heterozygosity studies have suggested the presence of at least one tumor suppressor gene on chromosome 10 involved in the formation of high grade gliomas. Recently, the PTEN gene, also termed MMAC1 or TEP1, on chromosomal band 10q23 has been identi®ed. Initial studies revealed mutations of PTEN in limited series of glioma cell lines and glioblastomas. In order to systematically evaluate the involvement of PTEN in gliomas, we have analysed the entire PTEN coding sequence by SSCP and direct sequencing in a series of 331 gliomas and glioneuronal tumors. PTEN mutations were detected in 20/142 glioblastomas, 1/7 giant cell glioblastomas, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas. No PTEN mutations were detected in 52 astrocytomas, 37 oligoastrocytomas, three subependymal giant cell astrocytomas, four pleomorphic xanthoastrocytomas, 15 ependymomas, 16 gangliogliomas and one dysembryoplastic neuroepithelial tumor. In addition, all tumors were examined for the presence of homozygous deletions of the PTEN gene; these were detected in 7 glioblastomas that did not have PTEN mutations. Therefore, PTEN mutations occur in approximately 20% of glioblastomas but are rare in lower grade gliomas. These ®ndings con®rm that PTEN is one of the chromosome 10 tumor suppressor genes involved in the development of glioblastomas.
Introduction
Human gliomas include such diverse entities as astrocytomas, oligodendrogliomas, mixed oligoastrocytoma and ependymoma. These entities can be further dierentiated and graded according to their approximate biological behavior (Kleihues et al., 1993) . The most frequent and most malignant glioma is glioblastoma multiforme (GBM), a lesion which may arise from lower-grade gliomas. Glioneuronal tumors share some features of gliomas, but contain an additional neuronal component and do not display the same tendency towards malignant progression.
Molecular genetic studies have demonstrated the involvement of various oncogenes and tumor suppressor genes in the process of brain tumor initiation and progression. Prominent examples of aected genes are TP53 which is mutated frequently in astrocytomas (Fults et al., 1992; von Deimling et al., 1992a) , CDKN2A which shows homozygous deletions in up to 40% of GBMs Schmidt et al., 1995) and CDK4 and EGFR which are ampli®ed in approximately 15% and 40% of GBM (Reifenberger et al., 1994a; Rollbrocker et al, 1996; von Deimling et al., 1993b) , respectively. The most frequent alteration in GBM, however, is loss of heterozygosity (LOH) on chromosome 10q which occurs in approximately 80% of GBM. This observation suggests a chromosome 10q tumor suppressor gene involved in the evolution or progression of these tumors (James et al., 1988; von Deimling et al., 1992b) . Deletion mapping in GBMs has suggested the presence of two tumor suppressor genes on the long and one on the short arm of chromosome 10, respectively (Albarosa et al., 1996; Steck et al., 1995) . Further evidence for the signi®cance of these putative tumor suppressor genes on chromosome 10 in the pathogenesis of gliomas was provided by microcellmediated chromosomal transfer. The glioma cell line U251-MG exhibited a suppression of growth in soft agar and of tumor formation in nude mice upon introduction of an intact chromosome 10 (Pershouse et al., 1993) . Similar experiments also point to a functional link between chromosome 10 genes in malignant gliomas and angiogenesis. Chromosome 10 transfer into the cell lines U251, U87 and LG11 followed by injection into nude mice inhibited neovascularization, a characteristic property of GBMs (Hsu et al., 1996) .
The PTEN gene on chromosome 10 shares homology with the cytoskeletal proteins tensin and auxilin and contains a protein phosphatase domain Steck et al., 1997 ). An intrinsic phosphatase activity of the PTEN product may have the potential to counteract protein tyrosine kinase activity (Li and Sun, 1997) . Recombinant PTEN dephosphorylates phospho-serine, -threonine and -tyrosine residues, perhaps indicating a dual specificity (Myers et al., 1997) . In a small series of GBMs, predominantly cell lines, both mutations and homozygous deletions aecting this gene were detected. Thus, PTEN at 10q23.3 is a strong candidate for a glioma-associated chromosome 10q tumor suppressor gene. In addition, germ line mutations in PTEN have been detected in patients with Cowden disease and Bannayan-Zonana syndrome Marsh et al., 1997) . Patients with Cowden disease, an autosomal dominantly inherited disorder characterized by hamartomas of multiple organs, macrocephaly and carcinoma of the breast and thyroid (Eng, 1997) may also develop a characteristic malformative/neoplastic lesion of the cerebellum, the gangliocytoma LhermitteDuclos (Albrecht et al., 1992; Eng et al., 1994; Padberg et al., 1991) . This lesion shares histopathological and biological features with many glioneuronal tumors, in particular the presence of a conspicuous neuronal population and a benign clinical course. These observations raise the question whether the PTEN gene may also be involved in the formation of glioneuronal tumors.
To provide a comprehensive analysis of the PTEN gene in glial and glioneuronal neoplasms, we have analysed a series of 331 tumors representing all major histopathological variants and grades by single strand conformation polymorphism (SSCP) analysis and direct sequencing for mutations in the entire coding region of the PTEN gene. In addition, we have also employed a PCR assay to detect homozygous deletions within the PTEN gene.
Results

SSCP alterations and point mutations in PTEN
Altered migration patterns were seen in 31 of 331 tumors. In order to exclude the presence of polymorphisms, all tumor-derived fragments exhibiting altered migration patterns were, in a second round of experiments, compared to those from corresponding germ line DNA. Of the 31 samples, four (IDs 268, 990, 2002 and 4204) carried a common polymorphism in exon 2 which has previously been described. Two other patients showed SSCP alterations in exon 5 (ID 206) and exon 8 (ID 492) in both tumor and lymphocyte DNA suggesting a rare polymorphism. The remaining 25 patients with altered SSCP migration had a wild type pattern in the constitutional DNAs, indicating that the altered SSCP fragments were representing somatic mutations. DNA sequencing con®rmed an altered nucleotide sequence in all samples with altered SSCP patterns (Table 1) . Somatic mutations were detected in 20/142 (14%) GBMs, 1/7 giant cell GBMs, 1/2 gliosarcomas, 2/22 (9%) oligodendrogliomas (WHO grade II) and 1/30 (3%) pilocytic astrocytomas (WHO grade I). No SSCP alterations were observed in the other tumor types. Mutations occurred in eight exons of PTEN; no alterations were seen in exon 9. The positions of the mutations are summarized in Figure 1 .
Of the 25 mutations, nine were missense mutations resulting in the exchange of a single amino acid, six were nonsense mutations resulting in a stop codon, three were frameshift mutations resulting in altered translation and a premature stop codon, four aected a splice site, two were in frame deletions of one amino acid each and one was an intronic mutation of unknown consequence. Two nonsense mutations 
DES=desmin; (A) ± annealing 508C, MgCl 2 2.0 mM, AA:BIS 1 : 80 12%; (B) ± annealing 508C, MgCl 2 1.5 mM, AA:BIS 1 : 60 10%; (C) ± annealing 548C, MgCl 2 1.5 mM, AA:BIS 1 : 80 12%; (D) ± annealing 508C, MgCl 2 1.5 mM, AA:BIS 1 : 80 12%; (E) ± annealing 558C, MgCl 2 1.5 mM, AA:BIS 1 : 80 12%; (F) ± annealing 558C, MgCl 2 1.5 mM, AA:BIS 1 : 30 12%; (G) ± annealing 508C, MgCl 2 1.5 mM, AA:BIS 1 : 100 14%; (H) ± annealing 508C Figure 2 .
PTEN mutations, patient age and survival
The average age of GBM patients with and without PTEN mutations was 56.4 and 54.7 yrs, respectively. Survival data were available from 66 GBM patients. Of these, 16 patients with a mean survival of 9.5 months exhibited PTEN alterations. Fifty patients without an aected PTEN gene survived on average 9.8 months.
Discussion
The present study of 331 glial and glioneuronal tumors demonstrates structural alterations of the PTEN gene in a signi®cant fraction of GBMs and occasional lower grade gliomas, but not in glioneuronal neoplasms. In summary, we detected PTEN mutations in 20/142 GBMs, 1/7 giant cell GBMs, 1/2 gliosarcomas, 1/30 pilocytic astrocytomas and 2/22 oligodendrogliomas. In addition, homozygous deletions in PTEN occurred in 7/141 GBMs, but not in the lower grade gliomas and in the glioneuronal tumors. Thus, somatic alterations in the PTEN gene were detected in 27/142 (19%) GBMs. A set of intronic and overlapping exonic primers was employed which allows the analysis of the entire coding sequence including splice sites and adjoining intronic sequences. Using this primer set enabled us to examine PTEN at the genomic DNA level. This will be useful for studies on archival material. Furthermore, this approach circumvents the potential problem of coexamining processed pseudogenes (Dahia and Eng, unpublished data).
The spectrum of PTEN mutations was comparable to preliminary studies which reported ®ve missense mutations, 11 truncating mutations and two in-frame deletions in gliomas Steck et al., 1997) . We detected nine missense mutations, 13 truncating mutations, two in-frame deletions and one intronic mutation. There were no obvious hotspots for PTEN mutations in our series, however, clusters of alterations were observed in a region spanning the small exons 3 and 4, the 5'-end of exon 6 and the 3'-end of exon 8.
Two nonsense mutations in exon 7 occurred twice each and both were con®rmed by an independent round of PCR, SSCP and sequencing experiments. Interestingly, one of the mutations occurring twice in this series, R233X has been previously described as germ line mutations associated with both Cowden syndrome and Bannayan-Zonana syndrome , autosomal dominant conditions characterized by multiple hamartomas (Eng, 1997) . This indicates, that Arg233, which contains a CpG dinucleotide, may be at increased risk for mutations. Of note, the phosphatase domain of PTEN was immediately aected in only two GBMs. Of the seven mutations proximal to the phosphatase domain, three were missense mutations, three aected a splice site and one resulted in a frameshift. This distribution is similar to all mutations detected in this study and indicates that the phosphatase domain is not a speci®c target of mutations in PTEN. However, a conformational eect of other mutations on the phosphatase motif cannot be excluded. Four of the 331 patients were heterozygous for a previously described polymorphism in exon 2. Due to the high frequency of allelic deletions, the frequency for this polymorphism has not been determined. However, for the rare allele, it was estimated to be 0.01. In addition, we noted two previously unknown and very rare polymorphisms aecting exon 5 and intron 7 in one of 331 patients each.
GBMs have been subdivided on the basis of speci®c, almost mutually exclusive genetic lesions. GBMs with TP53 mutations have been termed type 1, a subgroup including pediatric cases, adult patients of young age, patients with secondary GBM (i.e., with a history of a prior lower grade astrocytoma) and patients with the giant cell variant of GBM Louis et al., 1993; Meyer-Puttlitz et al., 1997; von Deimling et al., 1993b) . Type 2 GBMs do not carry TP53 mutations but display a high frequency of EGFR ampli®cation and generally aect patients with de novo GBMs (i.e., without a history of prior lower grade astrocytoma) of higher age. We, therefore, evaluated whether PTEN mutational status was associated with either GBM type 1 or type 2. 77/142 of the GBM in our series have previously been analysed for the presence of TP53 mutations. 3/18 (17%) type 1 GBM and 14/59 (24%) type 2 GBM had a PTEN mutation. Thus, GBM with and without TP53 mutations have a similar frequency of PTEN mutations, a ®nding which is further supported by the observation of LOH of markers on chromosome 10 in both GBM type 1 and type 2. However, in 6 secondary GBM, a subgroup of the type 1 GBM, no PTEN mutations were seen. In addition, the age and survival times of patients with and without PTEN mutations were virtually identical. Therefore, PTEN mutations do not appear to be of prognostic signi®cance among GBM patients.
LOH of markers on chromosome 10 is observed in approximately 70 ± 80% of GBM (Fujimoto et al., 1989; Fults et al., 1990; James et al., 1988; Rasheed et al., 1992; von Deimling et al., 1992b) . In contrast, PTEN mutations are found in a signi®cantly smaller percentage of these tumors. This discrepancy, in combination with molecular deletion and mapping studies, suggests the presence of at least a second GBM relevant tumor suppressor gene on the long arm of chromosome 10 (Albarosa et al., 1996; Steck et al., 1995) . We have recently identi®ed DMBT1 (deleted in malignant brain tumors) on chromosome 10q25.3-26.1, a gene bearing intragenic deletions in medulloblastomas and approximately 15% of GBM (Mollenhauer et al., 1997) . This gene is a strong candidate for a second tumor suppressor gene involved in the formation of GBM.
PTEN mutations were also observed in 2/22 oligodendrogliomas (WHO grade II) and 1/30 pilocytic astrocytomas (WHO grade I). This indicates that mutations in PTEN occur at low frequency in less malignant glial tumors. Of interest is the observation of PTEN mutations in oligodendrogliomas but not in any of 52 astrocytomas or anaplastic astrocytomas. This may provide additional evidence for separate molecular pathways in the development of oligodendroglial and astrocytic gliomas which have been proposed based on the dierent frequencies of allelic losses on chromosomes 1p and 19q (Reifenberger et al., 1994b; von Deimling et al, 1992c) and TP53 mutations (Maintz et al., 1997; Ohgaki et al., 1991) . In addition, LOH of chromosome 10 markers has been described in a fraction of oligodendroglial tumors (Reifenberger et al., 1994b) but only rarely in astrocytomas (WHO grades II and III). Although gangliogliomas share morphological features with glioneuronal hamartomas and a neuronal component as well as a benign clinical course with gangliocytoma of the cerebellum (Lhermitte-Duclos), we did not detect any PTEN mutation in our series of glioneuronal tumors.
In conclusion, the PTEN gene contributes to the pathogenesis of GBM. However, mutations are present in only approximately 20% of GBM, which strongly indicates the presence of additional tumor suppressor genes for GBM on chromosome 10q, such as DMBT1. PTEN mutations aect only a small fraction of lower grade gliomas and may be of some importance in oligodendrogliomas. Expression studies will provide more insight into PTEN involvement in gliomas. It remains to be examined, whether the dierential expression or mutation spectrum of PTEN versus DMBT1 may account for dierent properties of malignant gliomas.
Material and methods
Tumor specimens, histopathology and control DNA Tumor and corresponding blood samples from 331 patients were obtained from patients treated at the University Hospital Bonn, the Massachusetts General Hospital, Boston and the University Hospital Zurich between 1990 and 1997. All tumors were classi®ed by the same neuropathologist (AvD) according to the WHO guidelines (Kleihues et al., 1993) . All tumor specimens were examined microscopically prior to phenolic DNA extraction. 
SSCP analysis and direct sequencing
For analysis of the PTEN gene, a novel set of primers was generated (see Table 1 ). The primers cover the entire coding sequence as well as the exon/intron boundaries of the PTEN gene. PCR was performed in a volume of 10 ml containing 10 ng of DNA, 50 mM KCl, 10 mM Tris-HCl, 200 mM of each dNTP, 0.1% gelatin, 10 pmol of each primer, 1.0 to 2.0 mM MgCl 2 and 0.25 U Taq polymerase. Initial denaturation at 948C for 3 min was followed by 30 cycles on an automated thermal cycler (Biometra, GoÈ ttingen, Germany). These included denaturation at 948C for 30 s, annealing at 508 to 558C for 40 s and extension at 728C for 40 s. A ®nal extension step at 728C for 10 min was added. Single strand conformation polymorphism (SSCP) analysis was performed on a sequencing apparatus (Pokerface II, Hoefer, San Francisco, USA) using 10, 12 and 14% acrylamide gels, electrophoresis at 5 W to 10 W and variable temperatures for 14 h. Silver staining of the gels was performed as previously described (Bender et al., 1994; von Deimling et al., 1993a) . Aberrantly migrating SSCP bands were excised and the DNA was extracted as described (Wellenreuther et al., 1995) . After reampli®cation with the same set of primers the PCR products were sequenced on a semiautomated sequencer (Applied Biosystems, model 373A, Foster City, USA) using a Taq cycle sequencing kit (ABI PRISM dye terminator cycle sequencing ready reaction kit, Perkin Elmer, Alameda, USA). Each amplicon was sequenced bidirectionally.
Analysis for homozygous deletions
The PCR assay for the detection of homozygous deletions has been described previously . In brief, a 160 bp fragment including exon 4 (primers ex4f/ ex4r; see Table 1 ) of the PTEN gene was coampli®ed with a 171 bp fragment from intron 7 of the desmin (DES, chromosome 2) gene as a control. One primer of each pair was labeled with 5-carboxy-¯uorescein (IRD-41, MWG-Biotech, Ebersberg, Germany) at the 5' end. Dierential PCR was performed in a ®nal volume of 10 ml containing 10 ng DNA, 50 mM KCl, 1.5 mM MgCl 2 , 10 mM TRIS-HCl pH 8.3, 200 mM of each dNTP, 0.1% gelatin, 5 pmol of each primer, and 0.25 U Taq polymerase (Gibco-BRL). Initial denaturation at 948C for 3 min was followed by 28 cycles on a thermocycler (Hybaid, Omnigene, USA). These included denaturation at 948C for 40 s, annealing at 568C for 55 s and extension at 728C for 55 s. A ®nal extension step of 10 min at 728C was used. Fluorescent PCR products were separated on a 6% polyacrylamide gel and analysed on a semiautomatic DNA sequencer (Licor, Lincoln, Nebraska, USA). A quantitative analysis of the signal intensity was carried out with the ONE-DSCAN program (Scanalytics, Billerica, Massachusetts, USA).
